Pradaxa (dabigatran) is an anticoagulant medication which is used to prevent blood clot formation and reduce the risk of stroke, especially in people with atrial fibrillation or have a history of blood clots. Pradaxa was designed to be safer than older drugs but its use may have caused more than 500 bleeding deaths due to a lack of antidote. Boehringer Ingelheim has faced thousands of Pradaxa lawsuits due to serious complications, many of which have already been settled.

Sign up for our newsletter to get updates on drugs & medical devices

If you would like to sign up for our newsletter click the button below.

Sign Up For Newsletter

What Is Pradaxa?

Pradaxa (dabigatran) is an anticoagulant medication manufactured by Boehringer Ingelheim. Pradaxa is used to prevent blood clot formation in those who suffer atrial fibrillation (AF) and are at risk for stroke. It is also used in patients who have a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) and as a preventative for those conditions in hip replacement surgery.

Pradaxa was developed to be an alternative to the blood thinner, warfarin, which requires frequent blood clotting tests to ensure proper dosing and is known to have serious risks. While warfarin and Pradaxa treat the same condition, they work differently.

Pradaxa works to prevent blood clot formation by inhibiting the clotting protein, thrombin and does not require blood testing. Pradaxa is given as a daily dose of 75 to 150 mg. Patients with kidney problems may need lower dosages and should be carefully monitored.

Pradaxa was approved by the Food and Drug Administration (FDA) in October of 2010. By 2012, nearly 4 million prescriptions had been written and the drug had reached over $1 billion in sales. Though many patients may have been helped by Pradaxa, it has also caused severe side effects in thousands of people and has resulted in at least 500 deaths due to uncontrolled bleeding. An antidote to Pradaxa was not available until 2015, and many of these events and deaths may have been preventable or treatable.

In 2014, the company settled 4,000 lawsuits for $650 million but more patients may have been harmed as an antidote was not approved until 2015.

Pradaxa Lawsuit

Pradaxa (dabigatran) has been prescribed to millions of patients to help prevent strokes in patients with atrial fibrillation, deep vein thrombosis, pulmonary embolism, and hip replacement surgery. After roughly two years on the market, Pradaxa earned manufacturer Boehringer Ingelheim more than $1 billion in sales revenue.

Pradaxa was the first of a new category of anticoagulants which did not require blood testing for administration. Prior to Pradaxa, a blood thinner called Coumadin (warfarin) had been used for nearly 60 years, but it was thought to be inconvenient for patients and professionals to monitor.

At the time of its 2010 approval, blood-thinner Pradaxa had no available antidote. It was responsible for serious bleeding events, including death in thousands of patients. Since it was introduced, Boehringer Ingelheim has faced thousands of Pradaxa lawsuits.

In 2014, the company settled 4,000 lawsuits for $650 million but more patients may have been harmed as an antidote was not approved until 2015. A settlement offer for another 3,000 Connecticut lawsuits was made in November 2020, but it may be nearly a year before cases will be resolved.

Pradaxa Complications

In 2011 alone, the FDA received reports of 3,781 adverse events and 542 deaths associated with Pradaxa use. The Institute for Safe Medication Practices reported that Pradaxa was linked to more injury and death reports than any of the 800 drugs that it regularly monitors. Since Pradaxa is a blood thinner, a majority of the adverse reports and deaths were due to excessive bleeding.

Many patients suffered rectal, brain, and gastrointestinal bleeding and unfortunately, there was no antidote to reverse the fatal bleeding that Pradaxa can cause. An antidote to Pradaxa was not approved until 2015, with the introduction of Praxbind. Though bleeding caused by Pradaxa can now be treated in some cases, many patients were harmed, and some may still be at risk.

Pradaxa Side Effects

Like all medications, Pradaxa may cause side effects. In most cases, the side effects of Pradaxa are not sever but others can be serious or life-threatening.

Common Side Effects of Pradaxa

Like other anticoagulants, some Pradaxa patients may experience bruising or bleeding due to minor cuts. Patients who are taking Pradaxa should notify doctors and dentists prior to surgical procedures to help avoid bleeding complications.

Symptoms of bleeding may include:

  • Frequent nosebleed
  • Heavier than normal menstrual period
  • Pink or brown-tinged urine
  • Bruising
  • Unusual bleeding of the gums

Other common side effects may include:

  • Nausea
  • Indigestion
  • Heartburn
  • Stomach pain

Any side effects that occur while using Pradaxa should be reported to a healthcare professional.

Severe Pradaxa Side Effects

Pradaxa use may result in uncontrolled bleeding, which may be fatal. It may also increase the risk for heart attack and has caused severe allergic reactions in some patients.

Heart Attacks

Pradaxa has been shown to increase the risk of heart attack. A report, published in the Journal of the American College of Cardiology, assessed several trials with more than 30,000 patients. Results showed that Pradaxa users were 33 percent more likely to suffer heart attack when compared with warfarin.

Allergic Reactions

In rare cases, Pradaxa may cause severe allergic reactions. Pradaxa patients should seek immediate medical attention if they experience reaction symptoms such as severe dizziness, rash, trouble breathing, and itching and swelling that occurs in the tongue, throat, and face.

Pradaxa Bleeding

Uncontrolled bleeding is the number one cause of severe injury and death from Pradaxa use. In 2011, more than 2,300 bleeding events were reported. Because it works by inhibiting the clotting enzyme, thrombin, administration of clotting factors is not effective as an antidote and prior to 2015, bleeding caused by Pradaxa was not reversible.

Pradaxa manufacturer Boehringer Ingelheim recommended that bleeding episodes are treated with hemodialysis to remove Pradaxa from the bloodstream. This treatment has received criticism as many patients who suffer uncontrolled bleeding were not eligible for hemodialysis treatment. Many patients were simply monitored as Pradaxa was cleared from the body.

In 2015, a binding agent known as Praxbind was approved as an antidote. It may be effective at reversing hemorrhage when administered promptly but injury may still occur.

Increased risk factors for Pradaxa bleeding include:

  • Being over the age of 75
  • Stomach ulcers
  • Preexisting kidney problems
  • Preexisting or consistent stomach or intestinal bleeding
  • Taking other medications that also increase bleeding risk

Symptoms of uncontrolled bleeding may include:

  • Severe pain in abdomen or stomach
  • Vomiting with blood
  • Black, tarry stools
  • Abdominal swelling
  • Excessive tiredness
  • Confusion
  • Vision changes or slurred speech
  • Weakness on one side of body

At least 500 deaths have been caused by uncontrolled bleeding in patients taking Pradaxa and symptoms of uncontrolled bleeding should be treated as a medical emergency.

FDA Safety Warning

In June of 2011, the first FDA notice was issued for Pradaxa. A public alert notified healthcare professionals and the public about specific storage requirements, stating that Pradaxa should only be dispensed and stored in the original prescription container or blisterpak packaging. The notice stated that improper storage or exposure to moisture could contribute to product breakdown and reduced efficacy.

Due to the number of serious adverse event reports, in December 2011, the Food and Drug Administration issued the first of several warning notices regarding the safety of Pradaxa. The first warning only notified healthcare practitioners and the public that numerous bleeding events had occurred and were being evaluated by the agency. In November of 2012, the FDA issued an update to this warning, stating that recommendations regarding Pradaxa had not changed but indicating that a large study was underway to evaluate bleeding events.

In March of 2012, a report published in the Journal of the American College of Cardiology indicated that evaluation of 30,000 patients showed an increased risk of heart attack when compared to Coumadin. No changes were made to labeling as a result of this study however in December 2012, a new and separate safety warning was issued stating that Pradaxa should not be used in patients with mechanical prosthetic (artificial) heart valves. After a clinical study in Europe was halted, the FDA required that prescribing information include a contraindication against use in patients with artificial heart valves.

In April of 2013, Pradaxa’s manufacturer Boehringer Ingelheim, announced that they were adding a “black box warning” to the prescribing information. Information regarding an increased risk of clot formation and stroke when medication is suddenly discontinued was added to the top of prescribing information, enclosed in a black box. This boxed statement warning was similar to that included on other anticoagulants.

In May of 2014, the FDA issued another alert which warned that though elderly Pradaxa patients had a lower risk of stroke, cerebral bleeding, and death than similar Coumadin patients, the risk of major gastrointestinal bleeding was increased. The Medicare study used to provide this data also showed the two drugs had a similar heart attack risk. Again, no changes were required to be made to Pradaxa prescribing information.

Despite continuing reports of adverse events, Pradaxa was approved in November of 2015, to treat additional conditions including prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with hip replacements.

Pradaxa Antidote Approval

In October 2015, the FDA approved an antidote to Pradaxa through its fast-track “accelerated approval” pathway. Praxbind (idarucizumab) works to reverse Pradaxa’s anticoagulant effects by binding to the drug and its metabolites. It is given in emergency situations when bleeding cannot be controlled due to Pradaxa use. Though older medications like Coumadin already had antidotes, Pradaxa is the first of the “new” anticoagulants that can now be reversed.

Full approval for Praxbind was granted in April 2018, after final results from safety studies showed no unexpected results. Most patients show complete reversal of blood thinning effect within 4 hours of Praxbind administration after emergency bleeding event. Healthcare practitioners are advised to resume anticoagulant therapy when appropriate according to patient’s medical status.

Pradaxa Lawsuits

Boehringer Ingelheim has faced thousands of lawsuits filed by people who were injured while using Pradaxa. Many Pradaxa lawsuit claims that were filed in federal court were consolidated into a multidistrict litigation (MDL). Other Pradaxa lawsuits were consolidated in various state courts including nearly 3,000 cases in Connecticut superior court.

In 2014, Boehringer Ingelheim settled nearly 4,000 lawsuits for $650 million, regarding complications caused by Pradaxa use. Though the company has not disclosed additional settlements, many patients were not covered in the original claim, including some who experienced serious complications before an antidote became available in 2015.

In 2017, a federal court judge recommended shutdown of all remaining federal lawsuits, but no final action has been taken and Pradaxa lawsuits may remain in state and local courts. A settlement offer was also reportedly made to approximately 2,935 plaintiffs in Connecticut in November of 2020, however these cases are not expected to be resolved for up to 9 months.

Pradaxa Lawsuit Claims

Thousands of Pradaxa lawsuits were filed on the basis that Boehringer Ingelheim used deceptive marketing practices to promote the drug. Boehringer marketed the drug as a safer and more effective alternative to warfarin. However, evidence suggests that Pradaxa has equal or higher risks of internal bleeding. Additionally, Pradaxa was misrepresented as a “one-size-fits-all” treatment. Checkups, laboratory testing, and dosage adjustments were not required in the instructions.

Many claim that Boehringer was negligent by not establishing protocols for treating bleeding episodes. The company recommended dialysis treatment to help remove the drug from the bloodstream. However, medical professionals assert that dialysis treatment is unrealistic, unavailable, or difficult to tolerate by patients who may be experiencing a severe bleeding episode.

It is alleged that the company failed to adequately warn the public of the risks of using Pradaxa. By doing so, Boehringer is held accountable for willfully endangering the public by continuing to market and sell a defective drug. Many believe that Pradaxa was released onto the market prematurely, since there is no option for reversing the potentially deadly effects.

Boehringer Ingelheim had originally claimed that an antidote would not be needed and that serious events would be rare. In 2015 however, the company received expedited approval for Praxbind, a Pradaxa-specific antidote.

Settlements or awards for medical injury may include compensation for medical costs, lost wages, future medical costs and pain and suffering. Patients or loved ones of those who experienced serious injury such as hemorrhage or death, should have their case evaluated by legal experts.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.